(Q37933423)

25 August 2017

1 reference

title

Intravenous immunoglobulin in the treatment of autoimmune bullous dermatoses: an update (English)

1 reference

25 August 2017

Annette Czernik

1

1 reference

25 August 2017

Siavash Toosi

series ordinal

2

1 reference

25 August 2017

Jean-Claude Bystryn

series ordinal

3

1 reference

25 August 2017

Sergei A Grando

series ordinal

4

1 reference

25 August 2017

publication date

19 September 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

45

1 reference

25 August 2017

issue

1

1 reference

25 August 2017

page(s)

111-118

1 reference

Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

High-dose intravenous immunoglobulin (IVIG) therapy in autoimmune skin blistering diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

A randomized double-blind trial of intravenous immunoglobulin for pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Consensus statement on the use of intravenous immunoglobulin therapy in the treatment of autoimmune mucocutaneous blistering diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

A single cycle of rituximab for the treatment of severe pemphigus.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

High risk of death in elderly patients with extensive bullous pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Role of intravenous immunoglobulin in the treatment of bullous pemphigoid: analysis of current data

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Infantile bullous pemphigoid treated with intravenous immunoglobulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Comparison between intravenous immunoglobulin and conventional immunosuppressive therapy regimens in patients with severe oral pemphigoid: effects on disease progression in patients nonresponsive to dapsone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Intravenous immunoglobulin therapy in patients with ocular-cicatricial pemphigoid: a long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Intravenous immunoglobulin therapy for ocular cicatricial pemphigoid: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

High-dose intravenous immunoglobulins for the treatment of autoimmune mucocutaneous blistering diseases: evaluation of its use in 19 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Cicatricial pemphigoid with circulating IgA and IgG autoantibodies to the central portion of the BP180 ectodomain: beneficial effect of adjuvant therapy with high-dose intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Intravenous immunoglobulin therapy in patients with multiple mucosal involvement in mucous membrane pemphigoid

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Treatment of oral pemphigoid with intravenous immunoglobulin as monotherapy. Long-term follow-up: influence of treatment on antibody titres to human alpha6 integrin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Ocular cicatricial pemphigoid, keratomycosis, and intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Linear IgA bullous dermatosis in a patient with chronic renal failure: response to intravenous immunoglobulin therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Linear IgA bullous disease limited to the eye: a diagnostic dilemma: response to intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Successful treatment of linear IgA disease with salazosulphapyridine and intravenous immunoglobulins.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Intravenous immune globulin in the treatment of persistent pemphigoid gestationis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Synergistic actions of pemphigus vulgaris IgG, Fas-ligand and tumor necrosis factor-alpha during induction of basal cell shrinkage and acantholysis

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Novel mechanisms of target cell death and survival and of therapeutic action of IVIg in Pemphigus

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Novel mechanism for therapeutic action of IVIg in autoimmune blistering dermatoses

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

An imbalance in Akt/mTOR is involved in the apoptotic and acantholytic processes in a mouse model of pemphigus vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Comparison of cost of immune globulin intravenous therapy to conventional immunosuppressive therapy in treating patients with autoimmune mucocutaneous blistering diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

Adverse events associated with intravenous immunoglobulin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2F08916934.2011.606452

10.3109/08916934.2011.606452

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference